Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orotic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.36 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.36 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL29382652 | 1.00 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL1854526 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL366202 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL896843 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL422601 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL23859826 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL11903508 | 0.96 | ALDH1A1 (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL5148012 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL20518755 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 | |
| Orotic Acid SCHEMBL9726375 | 0.96 | LMNA (0.63) | LMNAALDH1A1CYP1A2GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031707-A | Composite targeting medicine for targeted alleviation of Alzheimer disease | 陈小军 | 2026-05-15 | — | — | CN | claimed |
| EP-4735120-A2 | CHEMICALLY INDUCED REPROGRAMMING TO REVERSE AGING | President and Fellows of Harvard College (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| EP-4659754-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2025-12-10 | — | — | EP | claimed |
| US-20250345362-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS PHARMA (BE) | 2025-11-13 | — | — | US | claimed |
| US-20250276008-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-09-04 | — | — | US | claimed |
| US-20250228889-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | LUENINGHOENER CATHERINE (US) | 2025-07-17 | — | — | US | claimed |
| WO-2025064524-A1 | CONTAMINANT PRECIPITATION COMPOSITIONS AND METHODS OF USE | LOCUS SOLUTIONS IPCO, LLC (US) | 2025-03-27 | — | — | WO | claimed |
| EP-4525889-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS Pharma (BE) | 2025-03-26 | — | — | EP | claimed |
| US-5223271-A | Topical; combatting molluscum contagiosum; skin lesions | EFAMOL HOLDINGS PLC (GB) | 1993-06-29 | — | — | US | claimed |
| EP-0484112-A2 | Use of lithium in the treatment or prophylaxis of Molluscum contagiosum | SCOTIA HOLDINGS PLC (GB) | 1992-05-06 | — | — | EP | claimed |
| US-5080909-A | Lithium Salt, Vidarabine, Synergistic | EFAMOL LIMITED (GB) | 1992-01-14 | — | — | US | claimed |
| EP-0432700-A2 | Use of lithium compounds for the treatment of combination skin | EFAMOL HOLDINGS PLC (GB) | 1991-06-19 | — | — | EP | claimed |
| EP-0132126-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1991-04-10 | — | — | EP | claimed |
| EP-0135312-B1 | ANTI-VIRAL COMPOSITIONS | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1989-12-27 | — | — | EP | claimed |
| US-4886670-A | LITHIUM SALT AND ACYLCLOVIR; TOPICAL; HERPES | EFAMOL LIMITED (GB) | 1989-12-12 | — | — | US | claimed |
| EP-0305097-A2 | Nutritional supplement | SCOTIA HOLDINGS PLC (GB) | 1989-03-01 | — | — | EP | claimed |
| EP-0135312-A2 | Anti-viral compositions | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1985-03-27 | — | — | EP | claimed |
| EP-0132126-A1 | Methods and compositions for the treatment of the skin | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | EIF2A, EIF6, TUFM | LMNA 2991/4885ALDH1A1 4636/4885CYP1A2 3992/4885 |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | AMPD1, TUFM, AMPD3 | LMNA 2516/4885ALDH1A1 4680/4885CYP1A2 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.